Prediction and Evaluation of Protein Farnesyltransferase Inhibition by Commercial Drugs

Journal of Medicinal Chemistry
2010.0

Abstract

The similarity ensemble approach (SEA) relates proteins based on the set-wise chemical similarity among their ligands. It can be used to rapidly search large compound databases and to build cross-target similarity maps. The emerging maps relate targets in ways that reveal relationships one might not recognize based on sequence or structural similarities alone. SEA has previously revealed cross talk between drugs acting primarily on G-protein coupled receptors (GPCRs). Here we used SEA to look for potential off-target inhibition of the enzyme protein farnesyltransferase (PFTase) by commercially available drugs. The inhibition of PFTase has profound consequences for oncogenesis, as well as a number of other diseases. In the present study, two commercial drugs, Loratadine and Miconazole, were identified as potential ligands for PFTase and subsequently confirmed as such experimentally. These results point toward the applicability of SEA for the prediction of not only GPCR-GPCR drug cross talk but also GPCR-enzyme and enzyme-enzyme drug cross talk.

Knowledge Graph

Similar Paper

Prediction and Evaluation of Protein Farnesyltransferase Inhibition by Commercial Drugs
Journal of Medicinal Chemistry 2010.0
Identification of Pharmacokinetically Stable 3,10-Dibromo-8-chlorobenzocycloheptapyridine Farnesyl Protein Transferase Inhibitors with Potent Enzyme and Cellular Activities
Journal of Medicinal Chemistry 1999.0
Potent and Selective Farnesyl Transferase Inhibitors
Journal of Medicinal Chemistry 2004.0
Design, Synthesis, and Pharmacological Evaluation of New Farnesyl Protein Transferase Inhibitors
Journal of Medicinal Chemistry 2002.0
A Prospective Cross-Screening Study on G-Protein-Coupled Receptors: Lessons Learned in Virtual Compound Library Design
Journal of Medicinal Chemistry 2012.0
Predicting New Indications for Approved Drugs Using a Proteochemometric Method
Journal of Medicinal Chemistry 2012.0
Design, Synthesis, and Biological Activity of 4-[(4-Cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as Potent and Selective Farnesyltransferase Inhibitors
Journal of Medicinal Chemistry 2004.0
Bridgehead modification of trihalocycloheptabenzopyridine lead to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability
Bioorganic & Medicinal Chemistry Letters 2004.0
Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase
Bioorganic & Medicinal Chemistry Letters 2003.0
Protein Farnesyltransferase Inhibitors Exhibit Potent Antimalarial Activity
Journal of Medicinal Chemistry 2005.0